CJC-1295 without DAC vs BPC-157 capsules: what the research compares
A research-use comparison of CJC-1295 without DAC and BPC-157 capsules: what each compound is, what published work measured, where the evidence base is stronger, and what remains uncharacterised.
CJC-1295 without DAC (also written CJC-1295 no DAC, and referred to in the literature as a growth hormone-releasing hormone analogue without the Drug Affinity Complex) is a synthetic GHRH analogue. It is classified among the growth hormone-releasing hormone (GHRH) analogues, a group that also includes sermorelin, tesamorelin and CJC-1295 with DAC [1]. The evidence block supplied for this page does not give a sequence, molecular formula or molecular weight for the compound, so none is stated here. BPC-157 capsules are an oral presentation of BPC-157, a synthetic pentadecapeptide derived from a sequence identified in gastric juice; the evidence block supplied for this page does not give its sequence, formula or molecular weight either, and does not give a capsule-specific pharmacokinetic dataset.
The published work on CJC-1295 without DAC centres on the GH-IGF-1 axis, specifically GHRH receptor-mediated signalling; the published work on BPC-157 centres on tissue-repair and cytoprotective endpoints rather than on a single named receptor family, and the evidence block does not name one.
Research Studies
CJC-1295 without DAC and GH-IGF-1 axis classification
CJC-1295 without DAC appears in the peer-reviewed literature as one of the GHRH analogues encountered in clinical practice and in online self-administration protocols. A review of performance-enhancing peptides marketed as research compounds lists it alongside sermorelin, tesamorelin and CJC-1295 with DAC within the GHRH analogue class, and alongside growth hormone secretagogues such as GHRP-2, GHRP-6, hexarelin and ipamorelin, the GH fragment AOD9604, and IGF-1 analogues [1]. That review frames the whole group as agents intended to modulate the GH-IGF-1 axis, and notes that they are marketed as research compounds while being used outside that framing [1].
CJC-1295 without DAC and HIV-associated visceral obesity
The most specific human study record in the evidence block is a multicentre, randomised, placebo-controlled, double-blind Phase 2 trial of CJC 1295 in patients with HIV-associated visceral obesity. Participants were treated for 12 weeks with a low dose, a high dose, or placebo, followed by a 6-week post-treatment follow-up period. The stated objective was to assess and compare efficacy, pharmacokinetics, safety and tolerability in that population [6]. The evidence block does not report the trial's results, effect sizes, or which formulation of CJC 1295 was administered, so no outcome is claimed here.
BPC-157 and musculoskeletal injury models
BPC-157 appears in the sports-medicine review literature among the unapproved peptides marketed directly to patients. Reviews of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance list BPC-157 within the gray-market group whose pharmacological mechanisms, safety profiles and regulatory status are presented alongside approved comparators [4][5]. The same body of work describes a parallel market of unapproved compounds operating largely outside regulatory oversight, driven by patient demand for accelerated injury recovery and performance enhancement [4][5].
BPC-157 capsules and route-of-administration evidence
The evidence block does not contain a study that measured BPC-157 delivered in capsule form against an injected comparator, and it does not contain capsule-specific bioavailability, absorption or stability data. What the block does contain is a general finding on the gray-market supply of research peptides: an evaluation of 6441 products in a large publicly available independent testing dataset examined purity, measured abundance and endotoxin burden, and compared cost against compounded and FDA-approved alternatives [2]. That study was not restricted to capsules and did not isolate BPC-157, so it cannot be used to characterise capsule performance.
CJC-1295 without DAC and BPC-157 capsules compared on measured endpoints
The two compounds are not measured against the same endpoints in the evidence block, which is the central structural fact of this comparison. The table below sets out what each is and what the supplied evidence does and does not cover.
| Attribute | CJC-1295 without DAC | BPC-157 capsules |
|---|---|---|
| Class as described in the evidence | GHRH analogue [1] | Unapproved peptide marketed direct to patients [4][5] |
| Pathway the work centres on | GH-IGF-1 axis [1] | Not named in the evidence block |
| Sequence, formula, molecular weight in evidence block | Not provided | Not provided |
| Human trial record in evidence block | Phase 2 randomised, placebo-controlled, double-blind trial, 12 weeks treatment plus 6 weeks follow-up, in patients with HIV-associated visceral obesity [6] | None specific to the capsule form |
| Reported outcomes in evidence block | None reported | None reported |
| Route-specific data in evidence block | Not provided | Not provided |
| Supply-quality data in evidence block | Covered only by a general gray-market dataset of 6441 products [2] | Covered only by the same general dataset [2] |
Where the evidence is stronger for CJC-1295 without DAC
On the supplied evidence, CJC-1295 without DAC has the more structured human record. It is named within a defined pharmacological class in a peer-reviewed review [1], and it is the subject of a registered Phase 2 randomised controlled trial with a specified population, dose arms, treatment duration and follow-up [6]. BPC-157 has no comparable trial record in the evidence block. That difference concerns study design and documentation, not measured effect: the evidence block reports no efficacy result for either compound.
Where the evidence is stronger for BPC-157 capsules
It is not. The evidence block contains no capsule-specific study for BPC-157, no head-to-head study between the two compounds, and no outcome data for either. BPC-157 is discussed in the review literature as part of the unapproved peptide group [4][5], and the broader peptide-supplement and injectable-peptide reviews note that clinical adoption has outpaced high-quality evidence and regulatory consensus [7][8]. Those statements describe the state of the literature; they do not favour either compound.
What is simply not known
- No sequence, molecular formula or molecular weight for either compound is given in the evidence block.
- No efficacy outcome is reported for CJC-1295 without DAC in the Phase 2 trial record [6], and no efficacy outcome is reported for BPC-157 in any form.
- No capsule-specific pharmacokinetic, absorption or stability data for BPC-157 appears in the evidence block.
- No head-to-head comparison of the two compounds appears in the evidence block.
- Purity, measured abundance and endotoxin burden have been evaluated across a large gray-market dataset of 6441 products [2], but the evidence block does not report results broken out by compound or by presentation.
- The evidence block does not establish a dose, a schedule or a clinical role for either compound in any population.
Regulatory and supply context common to both
Both compounds sit inside the same regulatory picture. Reviews of peptide therapies in sports medicine describe a gray market of unapproved compounds operating largely outside regulatory oversight, alongside approved peptide drugs that have been evaluated for both safety and efficacy [4][5]. Reviews of peptide and peptide-analogue use in sport describe a shift from anabolic-androgenic steroids toward peptides marketed as more selective alternatives [10]. A separate review of therapeutic peptides in gerontology notes that the field targets hallmarks of aging including tissue-repair impairment and hormonal decline, and that the evidence base and safety profiles vary across agents [3]. None of these sources reports a comparative finding between CJC-1295 without DAC and BPC-157 capsules.
If you are reading this for personal health reasons
The materials described here are sold for laboratory research only, and we do not provide dosing, administration or medical guidance of any kind. Nothing on this page is a recommendation for human use. If you are considering any compound for yourself, speak to a licensed clinician.
Sources
- [1] The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis — https://europepmc.org/article/PMC/PMC13322892
- [2] Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance — https://doi.org/10.20944/preprints202604.1748.v1
- [3] Therapeutic peptides in gerontology: mechanisms and applications for healthy aging — https://europepmc.org/article/PMC/PMC13095733
- [4] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://doi.org/10.20944/preprints202512.1011.v3
- [5] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://doi.org/10.20944/preprints202512.1011.v1
- [6] A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity — https://clinicaltrials.gov/study/NCT00267527
- [7] Peptide Supplements and Their Therapeutic Applications in Sports Medicine — https://pubmed.ncbi.nlm.nih.gov/42578445/
- [8] Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications — https://pubmed.ncbi.nlm.nih.gov/42160466/
- [9] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://pubmed.ncbi.nlm.nih.gov/41966639/
- [10] A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review — https://pubmed.ncbi.nlm.nih.gov/41880199/